Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Navocaftor - Lakefront Biotherapeutics

Next Previous
Drug Profile

Navocaftor - Lakefront Biotherapeutics

Alternative Names: ABBV 3067; GLPG 3067; GLPG-0367; SION-3067

Latest Information Update: 10 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
  • Developer AbbVie; Lakefront Biotherapeutics
  • Class Amines; Antifibrotics; Fluorinated hydrocarbons; Oxadiazoles; Phenyl ethers; Pyridines; Small molecules; Sulfones
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 08 May 2026 Galapagos NV is now called Lakefront Biotherapeutics
  • 16 Jul 2024 Sionna Therapeutics in-licenses Navocaftor from AbbVie
  • 22 Jun 2023 Abbvie terminates a phase II trial in Cystic fibrosis (Combination therapy, In adults) due to strategic considerations in United Kingdom, Slovakia, Hungary, Germany, Australia, New Zealand, Czech Republic, Netherlands, Belgium and USA (PO) (NCT04853368)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top